Estimates Revisions Capricor Therapeutics, Inc.
Stocks
CAPR
US14070B3096
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.25 USD | +0.14% |
|
-3.55% | -22.90% |
| 06-29 | Capricor Therapeutics Gets FDA Advisory Panel Meeting for Duchenne Therapy | MT |
| 06-29 | Capricor Therapeutics, Inc.(NasdaqGS:CAPR) dropped from Russell 3000E Index | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Stocks
- CAPR Stock
- Consensus Capricor Therapeutics, Inc.
- Estimates Revisions
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
